Abstract 2117P
Background
The provision of nutrients in adequate quantity and quality is essential for the treatment of low muscle mass, which is highly found in patients with lung cancer (LC). Identifying an early deficit in food consumption is recommended as a strategy to preserve muscle and weight compartments that directly impact treatment tolerance, functionality and quality of life. This study aimed to investigate whether caloric and protein intake at diagnosis are predictive of outcomes in patients with LC.
Methods
This is a prospective, observational study. Data were collected at the first nutritional consultation between January and December 2019 and consisted of nutritional risk screening for cancer patients, height, body weight, weight loss, calf circumference, handgrip strength measured using a dynamometer and 24-hour recall to estimate average food and macronutrient intake. Survival curves were generated by Kaplan-Meier analysis to assess the association between caloric and protein intake and 3-year mortality.
Results
A total of 50 patients with LC were included, 62% were female, 94% elderly, 88% with non-small cell lung cancer, 88% were diagnosed with disease stages III and IV, and 64% were smokers. Weight-adjusted mean daily intake of energy was 18.6 kcal/kg/day and protein 0.94g/kg/day, and 86% and 60% had lower energy and protein intakes, respectively, than the recommended for patients with cancer. Individuals with consumption greater than 1g/kg/day had significantly longer overall survival with 35,2 versus 21,9 months than those with consumption lower than the recommendation for patients with cancer (p=0.03). There was no statistical difference according to the caloric intake (>25kcal/kg/day versus <25kcal/kg/day) (p=0.20).
Conclusions
Caloric and protein intake at diagnosis is low in patients with LC, and a lower protein intake was a predictor of negative results. Nutritional interventions are low-cost and can be easily implemented as a strategy to modify these results and improve care for these individuals.
Clinical trial identification
Research Ethics Committee approval CAAE: 19918319.1.0000.5533.
Editorial acknowledgement
Legal entity responsible for the study
Grupo Oncoclínicas / Federal University of Rio de Janeiro.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06